JB Chemicals& Pharmaceuticals has dipped 5% to Rs 124 after reporting a net loss of Rs 6.5 crore for the third quarter ended December 31, 2013 (Q3FY14), mainly on account of one-time loss of Rs 65 crore due to revision of sale price of Russia-CIS OTC business undertaking. The company had posted a net profit of Rs 21.87 crore during the same period of previous fiscal.
Net sales of the company rose to Rs 234 crore during the third quarter, as against Rs 200 crore during the same period of previous fiscal, JB Chemicals & Pharmaceuticals Ltd said in a filing to the BSE.
Operating profit however, nearly double to Rs 37 crore from Rs 19 crore, due to higher sales coupled with favourable product mix, the company said.
The stock opened at Rs 126 and touched a low of Rs 119 on the BSE. A combined around 325,000 shares changed hands on the counter till 1000 hours on the BSE and NSE.
Net sales of the company rose to Rs 234 crore during the third quarter, as against Rs 200 crore during the same period of previous fiscal, JB Chemicals & Pharmaceuticals Ltd said in a filing to the BSE.
Operating profit however, nearly double to Rs 37 crore from Rs 19 crore, due to higher sales coupled with favourable product mix, the company said.
The stock opened at Rs 126 and touched a low of Rs 119 on the BSE. A combined around 325,000 shares changed hands on the counter till 1000 hours on the BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%